Form 4: Achieve Life Sciences CEO Awarded Performance Restricted Stock Units and Stock Options

Achieve Life Sciences CEO, Richard Alistair Stewart, was granted 157,500 performance restricted stock units and 67,500 stock options on January 13, 2025.

Summary

• Richard Alistair Stewart, CEO of Achieve Life Sciences, was granted 157,500 performance restricted stock units (PRSUs) and 67,500 stock options on January 13, 2025.
• The PRSUs vest upon the achievement of certain milestones, and will lapse if none are met.
• Each PRSU represents the right to receive one share of Achieve Life Sciences common stock.
• The stock options have an exercise price of $3.32 and vest over a 36-month period, with one-third vesting on the first anniversary of August 26, 2024, and the remainder vesting monthly over the following 24 months.
• The stock options expire on January 13, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard practice of executive compensation, which is generally viewed positively as it aligns management's interests with shareholders. The performance-based aspect of the PRSUs is also a positive sign.

Positives

• The granting of PRSUs and stock options to the CEO aligns his interests with the long-term success of the company.
• The vesting schedule of the stock options incentivizes the CEO to remain with the company for the long term.
• The performance-based vesting of the PRSUs encourages the CEO to achieve specific milestones.

Risks

• The PRSUs will lapse if the performance milestones are not met, potentially leading to a loss of incentive for the CEO.
• The value of the stock options is dependent on the future performance of the company's stock price.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

This type of equity-based compensation is common for executives in publicly traded companies, particularly in the biotech sector, to align their interests with shareholders and incentivize performance.

Comparison to Industry Standards

• Equity-based compensation, such as stock options and restricted stock units, is a standard practice for executive compensation in the biotechnology industry.
• Companies like Amgen, Gilead Sciences, and Biogen also use similar compensation structures to incentivize their executives.
• The vesting schedules and performance-based criteria are typical for these types of awards, ensuring long-term alignment with company goals.

Stakeholder Impact

• Shareholders may view the equity awards positively as they align the CEO's interests with the company's long-term success.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, performance restricted stock units, PRSU, executive compensation, insider trading, equity awards, vesting, ACHV, Richard Alistair Stewart, Achieve Life Sciences